NASDAQ:FATE Fate Therapeutics Q4 2024 Earnings Report $2.36 +0.56 (+31.11%) Closing price 04:00 PM EasternExtended Trading$2.38 +0.02 (+0.64%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Fate Therapeutics EPS ResultsActual EPS-$0.31Consensus EPS -$0.44Beat/MissBeat by +$0.13One Year Ago EPSN/AFate Therapeutics Revenue ResultsActual Revenue$1.86 millionExpected Revenue$1.57 millionBeat/MissBeat by +$291.00 thousandYoY Revenue GrowthN/AFate Therapeutics Announcement DetailsQuarterQ4 2024Date3/5/2025TimeBefore Market OpensConference Call DateWednesday, March 5, 2025Conference Call Time4:00PM ETUpcoming EarningsFate Therapeutics' Q1 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, May 14, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Fate Therapeutics Earnings HeadlinesFate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819May 5 at 8:30 AM | globenewswire.comFate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune DiseasesMay 4 at 9:00 AM | globenewswire.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.May 5 at 1:00 AM | American Alternative (Ad)Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comFate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 MeetingApril 30, 2026 | globenewswire.comFate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and ...April 16, 2026 | markets.businessinsider.comSee More Fate Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fate Therapeutics and other key companies, straight to your email. Email Address About Fate TherapeuticsFate Therapeutics (NASDAQ:FATE) is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access. Central to Fate’s pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development. Key programs include FT596, an NK cell candidate targeting CD19‐positive lymphoid malignancies; FT538, an NK cell therapy engineered for acute myeloid leukemia; and FT819, an iPSC‐derived CAR T‐cell product for multiple myeloma. The company’s platform also supports early‐stage efforts in autoimmune and inflammatory diseases, with preclinical programs exploiting novel mechanisms of immune modulation. Founded in 2007 and headquartered in La Jolla, California, Fate Therapeutics completed its initial public offering on the Nasdaq Stock Market in December 2013. The company has established strategic collaborations with pharmaceutical partners, including Biogen and Janssen Biotech, to advance selected cell therapy candidates. Clinical trials are underway across North America and in select international sites. Under the leadership of President and Chief Executive Officer Scott Wolchko, M.D., Fate Therapeutics continues to expand its manufacturing capabilities and clinical footprint. The company’s global efforts seek to bring standardized, off‐the‐shelf cell therapies to patients with limited treatment options, addressing unmet medical needs in oncology and immune dysregulation.View Fate Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Upcoming Earnings AppLovin (5/6/2026)ARM (5/6/2026)DoorDash (5/6/2026)Fortinet (5/6/2026)Marriott International (5/6/2026)Warner Bros. Discovery (5/6/2026)Apollo Global Management (5/6/2026)Cencora (5/6/2026)Cenovus Energy (5/6/2026)CVS Health (5/6/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
